^
Association details:
| Biomarker: | PD-1-L + PD-L1 elevation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study
Published date:
12/11/2023
Excerpt:
We retrospectively analyzed clinical data from 171 patients with advanced solid tumors who received nivolumab or pembrolizumab monotherapy regardless of treatment line....The sPD-1low/sPD-L1high combination was significantly associated with a shorter PFS and OS among patients with urothelial cancer…
DOI:
https://doi.org/10.3389/fimmu.2023.1325462
